Idiopathic ventricular fibrillation (VF) is a diagnosis of exclusion following a resuscitated cardiac arrest which remain unexplained after comprehensive cardiac, respiratory, metabolic and toxicological evaluation. However, idiopathic VF patients may share electrophysiological and clinical features. Polymorphic ventricular tachycardia, rapidly degenerating in VF, is often triggered by short-coupled premature ventricular contractions originating from the Purkinje system or localised areas of the inferior left or right ventricular wall. Secondary prevention with an automated implantable cardiac defibrillator is a cornerstone in idiopathic VF treatment. Ablation strategies may also play a role where a substrate is identified. The role of medical therapy in idiopathic VF is, however, poorly defined, mainly due to the lack of exploratory studies and the absence of randomised clinical trials. Use of IV calcium channel antagonists and isoprenaline for the acute management of VF has proven effective in idiopathic VF associated with short-coupled Torsades de Pointes and early repolarisation, respectively. Despite the lack of large-scale data, long-term prophylaxis with quinidine seems to be effective in suppressing VF recurrence, regardless of the associated electrocardiogram phenotype. Further understanding of the underlying mechanisms of idiopathic VF, including genetic studies, will play a role in the development of targeted pharmacological therapies.
Idiopathic ventricular fibrillation, sudden death, cardiac arrest, ventricular tachycardia, quinidine, isoproterenol
Chiara Scrocco, Bode Ensam and Elijah R Behr have nothing to declare in relation to this article.
Compliance with Ethics
This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.
Double-blind peer review.
The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.
August 16, 2019
18 October 2019
December 06, 2019
Elijah R Behr, Cardiology Clinical Academic Group, St George’s University Hospitals’ NHS Foundation Trust and Molecular and Clinical Sciences Institute, St George’s University of London, Cranmer Terrace, London SW17 0RE, UK. E: firstname.lastname@example.org
No funding was received in the publication of this article.
A survivor of cardiac arrest due to ventricular fibrillation (VF), without a cardiac, respiratory, metabolic, or toxicological explanation, is diagnosed with idiopathic VF.1 Idiopathic VF is estimated to account for approximately 5–7% of all out-of-hospital cardiac arrest cases.2,3 Furthermore, the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER) showed that 44% of out-of-hospital cardiac arrests without a clear presenting cause remained unexplained despite extensive investigations of the patient and their family members.4 CASPER also emphasised that the re-evaluation of patients with idiopathic VF, over time, may lead to a diagnosis in up to 20% of cases.5 More recent European data on 717 cardiac arrest survivors highlighted that a complete workup, including pharmacological provocation tests, identified diagnoses in most of the cases, with 6.8% labelled as idiopathic VF.6 These findings reflect the importance of comprehensive cardiac evaluation of cardiac arrest victims and family members for accurate diagnosis.
Idiopathic ventricular fibrillation
The term “idiopathic VF” is a diagnosis of exclusion; however, patients with idiopathic VF often share typical electrophysiological and clinical features. The first use of the term dates back to 1987, with the report by Belhassen of five cardiac arrest survivors (three men and two women, aged from 24–52 years) in whom myocardial ischaemia, metabolic or electrolyte disturbances, drug toxicity, pre-excitation, or prolonged QT interval had been excluded. In all subjects, a rapid poorly tolerated polymorphic ventricular tachycardia (VT) was induced by programmed ventricular stimulation, and in one case, a spontaneous polymorphic VT rapidly degenerating to VF was documented.7
In 1990, Leenhardt et al. described the mode of onset of spontaneous arrhythmias in 14 subjects with no structural heart disease and unexplained syncope, which consisted of a single premature ventricular contraction (PVC) with extremely short coupling interval (R-on-T phenomenon). The PVC occurred during a vulnerable period and therefore triggered a rapid polymorphic VT or VF. The electrocardiogram (ECG) pattern was termed “short-coupled Torsades de Pointe” (TdP) to highlight variable electrical activation of the arrhythmia with progressive changes in QRS morphology, amplitude, and polarity.8 These findings were confirmed by Viskin et al. in a cohort of unexplained cardiac arrest survivors; in 22 VF episodes recorded in nine subjects, the PVC initiating a rapid polymorphic VT had a coupling interval of 300 ± 52 ms. The episodes were not preceded by long–short RR sequences.9
The highly malignant nature of this non-pause dependent idiopathic polymorphic VT (i.e., not influenced by the sympathetic tone or by coronary hyperreactivity) was described further by Eisenberg et al. in a cohort of 15 idiopathic VF patients.10 The study showed that shorter PVC coupling intervals correlated with greater risk of spontaneous polymorphic VT and sudden cardiac death. The advent of electro-anatomical mapping techniques has allowed accurate identification of the site of origin of PVCs triggering VF in unexplained cardiac arrest survivors. Haïssaguerre and colleagues found that the foci are localised in the specialised Purkinje system in more than 85% of cases. These Purkinje beats, similar in morphology to fascicular tachycardias from the left ventricle or right ventricle, usually exhibited a short coupling interval.11,12 An example of short-coupled PVC triggering non-sustained polymorphic VT is shown in Figure 1.
In the last decade, case-control and epidemiological studies have described the association between J waves, defined as positive deflections immediately following the QRS complex and idiopathic VF.13–15 The presence of a J wave in the inferolateral ECG leads, which may or may be not be followed by ST segment elevation, is known as early repolarisation pattern. Early repolarisation pattern is a common ECG finding (estimated incidence 1–13%), usually considered innocent amongst healthy asymptomatic young individuals.1
Haïssaguerre et al. found that early repolarisation pattern was present in 31% of 206 case subjects with idiopathic VF cases and 5% of 412 matched subjects without heart disease; moreover, idiopathic VF subjects with early repolarisation pattern had a higher incidence of recurrent VF at follow-up (hazard ratio 2.1).13 The link between early repolarisation pattern and malignant arrhythmias is supported by the accentuation of the J wave before the onset of VF, and the observation of triggering PVCs coincident with the J wave at ECG. J waves are also associated with VF storms, defined as ≥3 VF episodes in 24 hours.13,16,17 The term early repolarisation syndrome has increasingly been used to identify patients with idiopathic VF and early repolarisation pattern at ECG (Figure 2A).1
The pathophysiology underlying early repolarisation syndrome is, however, still debated. According to animal models supported by ECG imaging studies, enhanced inward ion currents during phase 2 of the action potential (AP) are responsible for premature myocardial repolarisation.18,19 Increasing evidence supports an alternative hypothesis, according to which the J point elevation typical of early repolarisation pattern could be an expression of delayed depolarisation. High-density mapping studies in some early repolarisation syndrome survivors showed delayed, fragmented epi- and endocardial ECGs indicating local structural alterations in the inferior right and/or left ventricular walls coincident with the J wave.20 Similar findings have also been reported in a study involving 24 patients with no electrocardiographic phenotype. Localised areas of abnormal depolarisation were identified in 62%, highlighting the increasing role of depolarisation defects, with or without ECG manifestation, in the pathophysiology of sudden cardiac death in apparently normal hearts.21
Medical management of idiopathic ventricular fibrillation
Both guidelines and expert consensus documents agree that implantable cardiac defibrillator (ICD) implantation is recommended in patients with a diagnosis of idiopathic VF (class I). Optimal pharmacological treatment is less well defined due to the low prevalence of the condition and the absence of randomised case control studies.1,22 Table 1 summarises the current recommendations for medical therapy in idiopathic VF.1,22 The first drug trial in idiopathic VF was described by Belhassen and colleagues almost 30 years ago; in two of the first five described patients with inducible VF at electrophysiology study, electrical stimulation was repeated after intravenous disopyramide administration. In one case, disopyramide was effective in suppressing arrhythmias inducibility and long-term prophylaxis started (600 mg/daily), while in the other subject a self-terminating VT/VF could still be induced and disopyramide was substituted with quinidine. Four patients began long-term prophylaxis with oral quinidine (mean dosage 1,650 mg/daily) alone or, in two cases, combined with amiodarone. All patients remained asymptomatic during a mean follow-up of 52 months.7 The long-term efficacy of quinidine was confirmed by the same group over 20 years later in nine subjects with idiopathic VF or Brugada syndrome with previous cardiac arrest or syncope. Over a mean follow-up of 15 ± 7 years no recurrences of arrhythmias were documented and repeat electrophysiological studies failed to reproduce any sustained arrhythmias.23
Short-coupled Torsades de Pointe/polymorphic ventricular tachycardia
Only two case series studies, to date, described the response to antiarrhythmic agents in idiopathic VF cases triggered by short-coupled PVCs. In the study by Leenhardt et al.8 isoproterenol and atropine had mixed effects on suppressing short-coupled PVCs. During follow-up, two subjects treated with betablockers and one treated with verapamil died of sudden cardiac death. Overall, verapamil suppressed arrhythmia recurrence in seven out of 12 subjects. Verapamil, a slow calcium channel blocking agent, acts mostly on the sinoatrial (SA) and atrioventricular (AV) nodes causing depression of automaticity, slowing of conduction and increase in refractoriness. In addition, calcium-channel blockers can ameliorate arrhythmias caused by afterdepolarisations, or by localised areas of slow conduction. The proposed mechanisms for the effectiveness of verapamil in short-coupled TdP were lengthening of the coupling interval and suppression of repetitive PCVs. In the cohort described by Eisenberg et al.10 for patients with spontaneous, short-coupled TdP, treatment included both beta-blockers and/or calcium channel blockers; although again, these were not effective in the long term. According to the most recent guidelines, the use of IV calcium channel blockers should be considered for the acute management of VF storms or recurrent ICD discharges in subjects with short-coupled TdP (class IIb).22 Importantly, cases of idiopathic VF that responded well to quinidine also seem to be triggered by short-coupled PVCs.7,23 Thus, whilst not formally mentioned in the guidelines, quinidine can also be useful in suppression of PVCs.
Idiopathic ventricular fibrillation associated with J waves (early repolarisation syndrome)
Haïssaguerre et al. first described the effectiveness of different drug therapies in early repolarisation syndrome in 2009.24 In 16 subjects with VF storms, no response was achieved with beta-blockers (tested in 11 subjects), lidocaine/mexiletine (tested in nine subjects), and verapamil (tested in three subjects), while amiodarone was effective in one-third of cases. Isoproterenol infusion (1–5 μg/min) immediately suppressed all arrhythmias in seven patients when the sinus heart rate was increased above 120 beats/minute.24
Isoproterenol is a beta-1 and beta-2 adrenergic receptor agonist. The effects on beta-1 adrenergic receptors, primarily concentrated in the heart, include an increase in intracellular calcium, resulting in a steeper slope of the cardiac pacemaker AP phase 4; therefore, pacemaker cells reach the threshold at a faster rate, resulting in the characteristic decrease in basic cycle length. In the epicardium, this markedly diminishes the spike-and-dome appearance of the AP plateau and causes marked shortening of AP duration, due to a rate-dependent reduction of the transient outward current (ITo) secondary to incomplete recovery from inactivation.
In the endocardium ITo currents are weaker, resulting in little or no change in AP duration in response to increases in heart rate. Experimental models of early repolarisation syndrome suggest that cells in the inferior region of ventricular epicardium possess a higher level of ITo than those in the lateral LV and that this predisposes the inferior region to develop phase 2 re-entry and VT/VF. It also suggests that isoproterenol acts by restoring the epicardial AP dome by causing an inward shift in the balance of current.18
In the same case series, the efficacy of different pharmacological treatments over a follow-up of 69 ± 58 months was reported.24 Prophylaxis with standard antiarrhythmic drugs was poor in preventing recurrent VF: beta-blockers were effective in 2/16 subjects, verapamil in 0/4, mexiletine in 0/4, amiodarone in 1/7, and class Ic drugs in 2/9. Only quinidine/hydroquinidine was successful in all tested patients (9/9), decreasing recurrent VF from 33 ± 35 episodes to nil.
Similar results were obtained in another case study of 10 patients with idiopathic VF and VF storms: isoproterenol was effective in suppressing the arrhythmias and reducing the J waves amplitude at ECG (from 0.493 ± 0.198 mV prior to VF recurrence to 0.091 ± 0.101 mV [p<0.0001]), while trials with procainamide, lidocaine, verapamil, amiodarone, nifekalant, dofetilide, beta-blockers, and magnesium sulphate were unsuccessful.16 Quinidine was also effective, but was tested in only three subjects. Thus, quinidine may be useful, in addition to an ICD, for secondary prevention of VF in patients with a diagnosis of early repolarisation syndrome (class IIb).1
Mechanism of quinidine
The anti-arrhythmic effects of quinidine are thought, in part, to be due to inhibition of ITo and IKr currents causing a prolongation of both AP duration and refractory periods. Quinidine also blocks the fast sodium channel, therefore slowing the phase 0 of the AP and depressing spontaneous phase 4 diastolic depolarisations. Its effects are seen in both atrial and ventricular tissue, and the added anti-vagal action causes acceleration of AV nodal conduction. Quinidine appears effective across idiopathic VF with no definite ECG phenotype, short-coupled TdP, or associated with J waves. Its efficacy in short-coupled TdP could arguably be attributed to its negative dromotropic effect (reduction of conduction velocity) and the prolongation of the refractory period, making myocytes unexcitable by short-coupled PVCs and suppressing automaticity in Purkinje fibres.
There are different theories on the impact of quinidine on the mechanisms of arrhythmogenesis in early repolarisation syndrome. According to the repolarisation theory, a transmural heterogeneity of the AP phase 2 duration, mediated by ITo currents, leads to a net increase of repolarisation current in the epicardium relative to endocardium, resulting in local re-entry and polymorphic ventricular arrhythmias, providing both the trigger and substrate of VF.25 The ITo blocking effect of quinidine would restore the phase 2 dome and suppress this vulnerability. The depolarisation theory suggests that slow conduction areas, secondary to fibrosis and discontinuities in conduction, plays a primary role in the development of the ECG and arrhythmic manifestations. Changes in ionic currents (loss of function in INa and l-type ICa and gain of function of ITo; Figure 3) reduce the safety of conduction at high-resistance junctions, such as regions of extensive fibrosis or Purkinje fibre ventricular myocyte junctions, by altering the AP morphology during phase 2 as described above. Experimental studies in rabbits showed that ITo inhibition significantly enhances conduction between ventricular myocytes, suggesting that ITo current plays a major functional role in rate-dependent conduction abnormalities.26 Moreover, coupling-induced spontaneous activity in the Purkinje can trigger acute arrhythmias by increased gap junctional resistance at the Purkinje–ventricular interface.27 In this scenario, the block of ITo currents and the consequent restoration of a normal AP phase 2 dome would be a key factor for the suppression of arrhythmias by quinidine and the reduction of the J wave amplitude at ECG (Figure 2B).
Interestingly, both isoproterenol and quinidine are also effective in the acute management and long-term prophylaxis of arrhythmias in the Brugada and short QT syndromes.28–31 Further insights into the mechanisms of these genetically mediated ion channel diseases could help shed some light on the mechanism underlying early repolarisation syndrome.
The pharmacological treatment of idiopathic VF is poorly defined, mainly due to the lack of exploratory drug studies and the absence of randomised clinical trials and large-scale data. However, relatively robust evidence justifies the use of calcium channel antagonists and isoprenaline for the acute management of VF triggered by short-coupled TdP and associated with early repolarisation, respectively. Long-term prophylaxis with quinidine appears to be safe and effective in suppressing VF recurrence, regardless of the associated ECG phenotype. Further understandings on the underlying mechanisms of idiopathic VF, including genetic studies, will undoubtedly play a role in the development of targeted pharmacological therapies.